- Home
- CMMB vs FAAS Comparison
CMMB vs FAAS Comparison
Compare CMMB & FAAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- FAAS
- Stock Information
- Founded
- CMMB 2004
- FAAS 2021
- Country
- CMMB Israel
- FAAS Indonesia
- Employees
- CMMB N/A
- FAAS N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- FAAS
- Sector
- CMMB Health Care
- FAAS
- Exchange
- CMMB Nasdaq
- FAAS NYSE
- Market Cap
- CMMB 32.2M
- FAAS 34.6M
- IPO Year
- CMMB N/A
- FAAS N/A
- Fundamental
- Price
- CMMB $1.71
- FAAS $0.58
- Analyst Decision
- CMMB Strong Buy
- FAAS
- Analyst Count
- CMMB 2
- FAAS 0
- Target Price
- CMMB $9.00
- FAAS N/A
- AVG Volume (30 Days)
- CMMB 835.3K
- FAAS 375.4K
- Earning Date
- CMMB 03-06-2025
- FAAS 09-17-2024
- Dividend Yield
- CMMB N/A
- FAAS N/A
- EPS Growth
- CMMB N/A
- FAAS N/A
- EPS
- CMMB N/A
- FAAS N/A
- Revenue
- CMMB N/A
- FAAS $57,730,593.00
- Revenue This Year
- CMMB N/A
- FAAS N/A
- Revenue Next Year
- CMMB N/A
- FAAS N/A
- P/E Ratio
- CMMB N/A
- FAAS N/A
- Revenue Growth
- CMMB N/A
- FAAS 38.16
- 52 Week Low
- CMMB $0.58
- FAAS $0.38
- 52 Week High
- CMMB $2.55
- FAAS $12.97
- Technical
- Relative Strength Index (RSI)
- CMMB 32.89
- FAAS 47.80
- Support Level
- CMMB $1.66
- FAAS $0.45
- Resistance Level
- CMMB $2.06
- FAAS $0.67
- Average True Range (ATR)
- CMMB 0.16
- FAAS 0.11
- MACD
- CMMB -0.04
- FAAS 0.01
- Stochastic Oscillator
- CMMB 9.43
- FAAS 35.65
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
About FAAS DIGIASIA CORP
DigiAsia Corp operates as a holding company. The majority of DigiAsia's operations are currently conducted through its majority-owned entities, controlled entities and corporate joint venture. It is among the first embedded fintech as a service (EFaaS) companies in Indonesia serving business-to-business-to-consumer (B2B2C) customers, such as large corporations and state-owned enterprises, as well as business-to-business (B2B) customers, such as micro, small and medium-sized enterprise (MSME) merchants, across various segments. It aims to be a fintech-enabling platform in Southeast Asia by accelerating financial inclusion through its licenses and technology stack and combining the benefits of technological innovation with traditional financial services.